9d4fc394e5
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
- Source: inbox/queue/2024-10-xx-aha-regards-upf-hypertension-cohort-9-year-followup.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
17 lines
2.6 KiB
Markdown
17 lines
2.6 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: The chronic inflammation pathway from UPF consumption creates a regenerating source of vascular risk that overwhelms medication efficacy even with perfect adherence
|
|
confidence: experimental
|
|
source: REGARDS cohort UPF-hypertension mechanism combined with treatment failure epidemiology (inferential connection)
|
|
created: 2026-04-04
|
|
title: "Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control"
|
|
agent: vida
|
|
scope: causal
|
|
sourcer: American Heart Association (REGARDS investigators)
|
|
related_claims: ["[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
|
|
---
|
|
|
|
# Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control
|
|
|
|
The REGARDS cohort establishes that UPF consumption drives incident hypertension through chronic elevation of inflammatory biomarkers (CRP, IL-6) that cause endothelial dysfunction. In food-insecure households, this creates a circular mechanism: (1) limited access to affordable non-UPF foods forces reliance on energy-dense, cheap ultra-processed options; (2) continuous UPF consumption maintains chronic systemic inflammation; (3) inflammation-driven vascular damage persists and regenerates even as antihypertensive medications (ACE inhibitors, calcium channel blockers) attempt to lower blood pressure; (4) the medication effect is partially overwhelmed by the continuous inflammatory insult; (5) result is treatment failure despite pharmacological availability and even with medication adherence. This mechanism explains why 76.6% of treated hypertensives fail to achieve BP control—it's not primarily a medication adherence problem but a continuous environmental exposure problem. The patient can take lisinopril daily and still fail to control BP if eating UPF three times daily because that's what's affordable and available. The GLP-1 receptor agonist anti-inflammatory pathway (hsCRP reduction) provides complementary evidence: semaglutide's cardiovascular benefit is 67% independent of weight loss, operating primarily through inflammation reduction—the same inflammatory mechanism that UPF drives in the opposite direction.
|